

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT2942405

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
NOVARTIS PHARMACEUTICALS CORPORATION	05/11/2011
NOVARTIS PHARMA AG	05/11/2011
NOVARTIS AG	05/11/2011
RECEIVING PARTY DATA	
Name:	MEDA PHARMA S.AR.L
Street Address:	43, AVENUE JOHN FITZGERALD KENNEDY
City:	LUXEMBOURG
State/Country:	LUXEMBOURG
Postal Code:	L-1855
PROPERTY NUMBERS Total: 1	
Property Type	Number
Patent Number:	7514554
CORRESPONDENCE DATA	
Fax Number:	(516)228-8516
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	5162248484
Email:	mleone@dilworthbarrese.com
Correspondent Name:	DILWORTH & BARRSE, LLP
Address Line 1:	1000 QWOODBURY ROAD
Address Line 2:	SUITE 405
Address Line 4:	WOODBURY, NEW YORK 11797
ATTORNEY DOCKET NUMBER:	167-120
NAME OF SUBMITTER:	ANN R. POKALSKY
SIGNATURE:	/Ann R. Pokalsky/
DATE SIGNED:	07/17/2014
Total Attachments: 16	
source=Assignment Novartis-MEDA#page1.tif	
source=Assignment Novartis-MEDA#page2.tif	
source=Assignment Novartis-MEDA#page3.tif	
source=Assignment Novartis-MEDA#page4.tif	
PATENT	

source=Assignment Novartis-MEDA#page5.tif
source=Assignment Novartis-MEDA#page6.tif
source=Assignment Novartis-MEDA#page7.tif
source=Assignment Novartis-MEDA#page8.tif
source=Assignment Novartis-MEDA#page9.tif
source=Assignment Novartis-MEDA#page10.tif
source=Assignment Novartis-MEDA#page11.tif
source=Assignment Novartis-MEDA#page12.tif
source=Assignment Novartis-MEDA#page13.tif
source=Assignment Novartis-MEDA#page14.tif
source=Assignment Novartis-MEDA#page15.tif
source=Assignment Novartis-MEDA#page16.tif

INTELLECTUAL PROPERTY ASSIGNMENT AGREEMENT

This INTELLECTUAL PROPERTY ASSIGNMENT AGREEMENT (the "Agreement") is entered into as of the 11th day of May, 2011, by and among Novartis Pharmaceuticals Corporation, a Delaware corporation ("NPC"), Novartis Pharma AG, a Swiss company ("NPHAG") and Novartis AG, a Swiss company ("Novartis AG" and, together with NPC and NPHAG, "Novartis"), and Meda Pharma SARL, a Luxembourg company (the "Purchaser"). Capitalized terms used and not defined in this Agreement have their respective meanings as defined in the Asset Purchase Agreement (as defined below).

WHEREAS, Novartis and the Purchaser have entered into that certain Asset Purchase Agreement dated as of April 6, 2011 (the "Asset Purchase Agreement"); and

WHEREAS, pursuant to the Asset Purchase Agreement, Novartis has agreed to sell, transfer, assign and convey, to the Purchaser and the Purchaser has agreed to purchase and acquire from Novartis the Trademarks (set forth in Schedule A), the Domain Names (set forth in Schedule B) and the Patents (set forth in Schedule C).

NOW, THEREFORE, in consideration of the promises and mutual agreements set forth in the Asset Purchase Agreement and other valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:

1. Upon the terms and conditions contained in the Asset Purchase Agreement, (i) Novartis hereby sells, transfers, assigns and conveys, free and clear of all Encumbrances (other than Permitted Encumbrances), to the Purchaser all of Novartis' rights, titles and interests in and to the Trademarks (and all goodwill associated therewith), Domain Names and Patents, and (ii) the Purchaser hereby assumes and will be responsible for and pay, perform and discharge when due all Liabilities, including payment of any fees required to maintain any registrations and applications for registration, arising from the ownership or use of the Trademarks, Domain Names and Patents on and after the date hereof.

2. Novartis hereby authorizes and requests any official of any state or foreign country whose duty is to issue intellectual property registrations, to (i) issue all registrations from any applications for registrations and (ii) transfer any applications or registrations, as applicable, in each case that are included in the Trademarks, Domain Names and Patents to Purchaser at Purchaser's expenses.

3. This Agreement shall be governed by and construed in accordance with the laws of the State of New York, without giving effect to the conflicts of laws provision thereof.

4. This Agreement shall be subject to the terms and conditions of the Asset Purchase Agreement, including but not limited to the representations, warranties, covenants, agreements and indemnities of any Party.

5. For the convenience of the Parties hereto, this Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same agreement.

[Signature page follows]

IN WITNESS WHEREOF, the parties hereto have executed this Intellectual Property Assignment Agreement as of the date first set forth above.

Novartis Pharmaceuticals Corporation

By: ANDRE WYSS
HEAD, PHARMA NORTH AMERICA AND PRESIDENT,
NOVARTIS PHARMACEUTICALS CORPORATION

Name:
Title:

Novartis Pharma AG

By: _____
Name:
Title:

By: _____
Name:
Title:

Novartis AG

By: _____
Name:
Title:

By: _____
Name:
Title:

MEDA PHARMA SARI

By: _____
Name:
Title:

[Signature page to Intellectual Property Assignment Agreement]


IN WITNESS WHEREOF, the parties hereto have executed this Intellectual Property Assignment Agreement as of the date first set forth above.

Novartis Pharmaceuticals Corporation


By: _____
Name:
Title:

Novartis Pharma AG

By:  _____
Name: **Amal Khouri**
Title: **Head Patenting General Medicines and Mature Products**

By:  _____
Name: **Bettina Marion Jopp**
Title: **Senior Legal Counsel**

Novartis AG

By:  _____
Name: **J.-M. Séquier**
Title: **Business Development & Licensing
Authorised Signatory**

By:  _____
Name: **Sarah Clements**
Title: **Authorised Signatory**

MEDA PHARMA SARL

By: _____
Name:
Title:

[Signature page to Intellectual Property Assignment Agreement]

IN WITNESS WHEREOF, the parties hereto have executed this Intellectual Property Assignment Agreement as of the date first set forth above.

Novartis Pharmaceuticals Corporation

By: _____
Name:
Title:

Novartis Pharma AG

By: _____
Name:
Title:

By: _____
Name:
Title:

Novartis AG

By: _____
Name:
Title:

By: _____
Name:
Title:

MEDA PHARMA SARL

By: 
Name: INGRID HENNING
Title: MANAGING DIRECTOR

[Signature page to Intellectual Property Assignment Agreement]

SCHEDULE C

PATENTS
Compound

PROTECTION TYPE	FAMILY NUMBER	CTRY	TYPE	FLING DATE	FLING NUMBER	PUBLICATION	GRANT NUMBER	GRANT DATE	STATUS	EXPIRY
Compound	PAT900-9581-AT-EPA	AT	EPA1	07 Nov 1990	90810854.1	15 Mai 1991	427680	23 Aug 1995	EXP	07 Nov 2010
Compound	PAT900-9581-AT-SPC	AT	SPC1	17 Mrz 2003	SZ12/2003		SZ12/2003	09 Jun 2005	GRT	07 Nov 2015
Compound	PAT900-9581-AU-EXT	AU	EXT1	13 Okt 2003	65843/90		640963	31 Mrz 2004	ANNP	07 Nov 2015
Compound	PAT900-9581-AU-NP	AU	NP1	07 Nov 1990	65843/90		640963	07 Jan 1994	ANNP	07 Nov 2010
Compound	PAT900-9581-BE-EPA	BE	EPA1	07 Nov 1990	90810854.1	15 Mai 1991	427680	23 Aug 1995	EXP	07 Nov 2010
Compound	PAT900-9581-BE-SPC	BE	SPC1	24 Apr 2003	2003C/014		2003C/014	07 Okt 2003	GRT	07 Nov 2015
Compound	PAT900-9581-BR-PCP	BR	PCP1	15 Apr 1997	PI1100291-3	05 Mai 1998	PI1100291-3	18 Mai 1999	EXP	07 Nov 2010
Compound	PAT900-9581-CA-NP	CA	NP1	09 Nov 1990	2029694		2029694	08 Mai 2001	EXP	09 Nov 2010
Compound	PAT900-9581-CH-EPA	CH	EPA1	07 Nov 1990	90810854.1	15 Mai 1991	427680	23 Aug 1995	EXP	07 Nov 2010
Compound	PAT900-9581-CH-SPC	CH	SPC1	27 Aug 2003	C00427680/01	30 Sep 2003	C00427680/01	31 Jan 2006	GRT	06 Nov 2015
Compound	PAT900-9581-CL-NP	CL	NP1	28 Feb 2003	378/2003				ABD	
Compound	PAT900-9581-CL-REV	CL	REV1	05 Jul 2002	1485/2002	17 Okt 2003			PUB	07 Nov 2010
Compound	PAT900-9581-DE-EPA	DE	EPA1	07 Nov 1990	90810854.1	15 Mai 1991	69021833.8	23 Aug 1995	EXP	07 Nov 2010
Compound	PAT900-9581-DE-NP	DE	NP1	09 Nov 1988	F3937336.3				ABD	
Compound	PAT900-9581-DE-SPC	DE	SPC1	09 Okt 2002	10299040.9		10299040.9	04 Apr 2006	GRT	07 Nov 2015
Compound	PAT900-9581-DK-EPA	DK	EPA1	07 Nov 1990	90810854.1	15 Mai 1991	427680	23 Aug 1995	EXP	07 Nov 2010
Compound	PAT900-9581-DK-SPC	DK	SPC1	08 Aug 2002	CA200200016		CA200200016	22 Sep 2008	GRT	07 Nov 2015
Compound	PAT900-9581-EC-PCP	EC	PCP1	29 Dez 1994	SP94-1320				ABD	10 Aug 2006
Compound	PAT900-9581-EP-EPA	EP	EPA1	07 Nov 1990	90810854.1	15 Mai 1991	427680	23 Aug 1995	EXP	07 Nov 2010
Compound	PAT900-9581-ES-EPA	ES	EPA1	07 Nov 1990	90810854.1	15 Mai 1991	427680	23 Aug 1995	EXP	07 Nov 2010
Compound	PAT900-9581-ES-SPC	ES	SPC1	08 Apr 2003	200300011		200300011	30 Mai 2005	GRT	07 Nov 2015
Compound	PAT900-9581-FR-EPA	FR	EPA1	07 Nov 1990	90810854.1	15 Mai 1991	427680	23 Aug 1995	EXP	07 Nov 2010
Compound	PAT900-9581-FR-SPC	FR	SPC1	27 Aug 2003	03C033	07 Nov 2003	03C033	11 Feb 2005	GRT	06 Nov 2015
Compound	PAT900-9581-GB-EPA	GB	EPA1	07 Nov 1990	90810854.1	15 Mai 1991	427680	23 Aug 1995	EXP	07 Nov 2010
Compound	PAT900-9581-GB-SPC	GB	SPC1	31 Mrz 2003	SPC/GB03/015		SPC/GB03/015	15 Jan 2004	GRT	06 Nov 2015
Compound	PAT900-9581-GR-EPA	GR	EPA1	07 Nov 1990	90810854.1	15 Mai 1991	427680	23 Aug 1995	EXP	07 Nov 2010
Compound	PAT900-9581-GR-SPC	GR	SPC1	21 Apr 2003	20030803008	22 Apr 2004	8000168	16 Jan 2006	GRT	08 Nov 2015

PATENT

Compound	PAT900-9581-HK-FPR	HK	FPR1	16 Jan 1996	48/96				300/96	15 Feb 1996	EXP	07 Nov 2010
Compound	PAT900-9581-HU-PCP	HU	PCP1	02 Jun 1995	161/95				210900	28 Jul 1995	GRT	09 Nov 2010
Compound	PAT900-9581-HU-SPC	HU	SPC1	18 Jun 2004	S0400001				S000028	24 Aug 2006	GRT	09 Nov 2015
Compound	PAT900-9581-IE-NP	IE	NP1	08 Nov 1990	4023/90				69974	27 Sep 1996	EXP	08 Nov 2010
Compound	PAT900-9581-IL-EXT	IL	EXT1	07 Nov 1990	96268				96268	22 Sep 2005	GRT	07 Nov 2015
Compound	PAT900-9581-IL-NP	IL	NP1	07 Nov 1990	96268				96268	24 Okt 1996	EXP	07 Nov 2010
Compound	PAT900-9581-IT-EPA	IT	EPA1	07 Nov 1990	90810854.1				427680	23 Aug 1995	EXP	07 Nov 2010
Compound	PAT900-9581-IT-SPC	IT	SPC1	25 Mrz 2005	C-UB2005CCP879				C-UB2005CCP879	20 Jul 2005	GRT	07 Nov 2015
Compound	PAT900-9581-JP-NP	JP	NP1	08 Nov 1990	305894/90				2750302	27 Feb 1998	EXP	08 Nov 2010
Compound	PAT900-9581-KR-EXT	KR	EXT1	08 Nov 1990	18016/90				166074	22 Sep 1998	GRT	04 Jan 2011
Compound	PAT900-9581-KR-NP	KR	NP1	08 Nov 1990	18016/90				166074	22 Sep 1998	GRT	08 Nov 2010
Compound	PAT900-9581-LU-EPA	LU	EPA1	07 Nov 1990	90810854.1				427680	23 Aug 1995	EXP	07 Nov 2010
Compound	PAT900-9581-LU-SPC	LU	SPC1	23 Apr 2003	91021				91021	24 Jun 2003	GRT	07 Nov 2015
Compound	PAT900-9581-LV-NP	LV	NP1	17 Jul 1996	253/96				11621	20 Apr 1997	ABD	05 Aug 2017
Compound	PAT900-9581-MY-NP	MY	NP1	08 Nov 1990	P190001975				MY-111430-A	31 Mai 2000	GRT	31 Mai 2015
Compound	PAT900-9581-NG-NP	NG	NP1	07 Nov 1990	228/90				11473	30 Jun 1993	EXP	07 Nov 2010
Compound	PAT900-9581-NL-EPA	NL	EPA1	07 Nov 1990	90810854.1				427680	23 Aug 1995	EXP	07 Nov 2010
Compound	PAT900-9581-NL-SPC	NL	SPC1	05 Sep 2003	300134				300134	08 Mrz 2004	GRT	06 Nov 2015
Compound	PAT900-9581-NZ-NP	NZ	NP1	07 Nov 1990	235991				235991	16 Sep 1993	EXP	07 Nov 2010
Compound	PAT900-9581-PH-NP	PH	NP1	07 Nov 1990	1-1990-41508				28375	12 Jul 1994	GRT	12 Jul 2011
Compound	PAT900-9581-PK-NP	PK	NP1	07 Nov 1990	461/90				132417	03 Feb 1993	EXP	07 Nov 2006
Compound	PAT900-9581-PY-REV	PY	REV1	24 Jan 2001	1364/01				4044	21 Nov 2001	ABD	
Compound	PAT900-9581-RO-PCP	RO	PCP1	04 Sep 1998	98-20171				2144T	30 Nov 2001	EXP	07 Nov 2010
Compound	PAT900-9581-RO-SPC	RO	SPC1	09 Mrz 2007	C/0010				C2007010	29 Mai 2009	GRT	07 Nov 2015
Compound	PAT900-9581-SA-NP	SA	NP1	15 Dez 1990	90110169				281	05 Apr 2005	GRT	15 Dez 2010
Compound	PAT900-9581-SE-EPA	SE	EPA1	07 Nov 1990	90810854.1				427680	23 Aug 1995	EXP	07 Nov 2010
Compound	PAT900-9581-SE-SPC	SE	SPC1	12 Sep 2003	0390020-6				0390020-6	05 Jul 2005	GRT	07 Nov 2015
Compound	PAT900-9581-SG-FPR	SG	FPR1	29 Mrz 1997	9790499-9				9790499-9	29 Mrz 1997	EXP	07 Nov 2010
Compound	PAT900-9581-TT-NP	TT	NP1	02 Mai 2001	TT/A/2001/00083				TT/A/2003/00058	06 Jun 2003	EXP	07 Nov 2010
Compound	PAT900-9581-TW-NP	TW	NP1	10 Nov 1990	79-109503				NI-49667	19 Nov 1991	EXP	10 Nov 2010
Compound	PAT900-9581-US-DIV	US	DIV1	18 Jul 1994	08276276				5912238	15 Jun 1999	GRT	15 Jun 2016
Compound	PAT900-9581-US-NP	US	NP1	05 Nov 1990	609280						ABD	
Compound	PAT900-9581-US-NP03	US	NP3	06 Jun 1995	081470855						ABD	06 Jun 2015

Compound	PAT900-8581-ZA-NP	ZA	NP1	09 Nov 1990	90/9024	90/9024	29 Jul 1992	EXP	09 Nov 2010
----------	-------------------	----	-----	-------------	---------	---------	-------------	-----	-------------

Foam Formulation

PROTECTION TYPE	FAMILY NUMBER	CTRY	TYPE	FILING DATE	FILING NUMBER	PUBLICATION	GRANT NUMBER	GRANT DATE	STATUS	EXPIRY
Foam Formulation	PAT033723-AU-PCT	AU	PCT1	07 Apr 2005	2005230401	27 Nov 2008	2005230401	12 Mrz 2009	GRT	07 Apr 2025
Foam Formulation	PAT033723-BR-PCT	BR	PCT1	07 Apr 2005	PI0509708-8	18 Sep 2007			TAX	07 Apr 2025
Foam Formulation	PAT033723-CA-PCT	CA	PCT1	07 Apr 2005	2556993				DEPL	07 Apr 2025
Foam Formulation	PAT033723-CN-PCT	CN	PCT1	07 Apr 2005	200580007920.5	14 Mrz 2007	200580007920.5	09 Jun 2010	GRT	07 Apr 2025
Foam Formulation	PAT033723-EP-EPT	EP	EPT1	07 Apr 2005	05733580.4	27 Dez 2006			PUB	07 Apr 2025
Foam Formulation	PAT033723-GB-NP	GB	NP1	08 Apr 2004	0408070.1				ABD	08 Apr 2024
Foam Formulation	PAT033723-HK-FPR	HK	FPR1	23 Mai 2007	07105470.1	10 Aug 2007			PUB	07 Apr 2025
Foam Formulation	PAT033723-IN-PCT	IN	PCT1	07 Apr 2005	3725/CHENP/06				DEPL	07 Apr 2025
Foam Formulation	PAT033723-JP-PCT	JP	PCT1	07 Apr 2005	2007-506729	15 Nov 2007			PUB	07 Apr 2025
Foam Formulation	PAT033723-KR-PCT	KR	PCT1	07 Apr 2005	2006-7020770				DEPL	07 Apr 2025
Foam Formulation	PAT033723-MX-PCT	MX	PCT1	07 Apr 2005	PA/A/06/011585	20 Apr 2007	275654	03 Mai 2010	GRT	07 Apr 2025
Foam Formulation	PAT033723-RU-PCT	RU	PCT1	07 Apr 2005	2006138998		2375044	10 Dez 2009	GRT	07 Apr 2025
Foam Formulation	PAT033723-US-PCT	US	PCT1	07 Apr 2005	11/547226	31 Jul 2008			PUB	07 Apr 2025
Foam Formulation	PAT033723-WO-PCT	WO	PCT1	07 Apr 2005	PCT/EP2005/003669	20 Okt 2005			PUB	

PATENT

REEL: 033332 FRAME: 0177

Marketed Formulation

PROTECTION TYPE	FAMILY NUMBER	CTRY	TYPE	FILING DATE	FILING NUMBER	PUBLICATION NUMBER	GRANT NUMBER	GRANT DATE	STATUS	EXPIRY
Marketed Formulation	PAT100-8185-US-CNT03	US	CNT3	23 Jan 2001	09/767656	18 Okt 2001	6352998	05 Mrz 2002	GRT	26 Okt 2015
Marketed Formulation	PAT100-8185-US-CNT	US	CNT1	30 Apr 1999	09/302763				ABD	26 Okt 2015
Marketed Formulation	PAT100-8185-US-CNT02	US	CNT2	20 Jan 2000	09/488283				ABD	26 Okt 2015
Marketed Formulation	PAT100-8185-US-PCT	US	PCT1	26 Okt 1995					ABD	26 Okt 2015

Ointment Formulation

PROTECTION TYPE	FAMILY NUMBER	CTRY	TYPE	FILING DATE	FILING NUMBER	PUBLICATION NUMBER	GRANT NUMBER	GRANT DATE	STATUS	EXPIRY
Ointment Formulation	PAT030724-AR-NP	AR	NP1	17 Mai 2000	P000102368	23 Jul 2003			PUB	17 Mai 2020
Ointment Formulation	PAT030724-AT-EPT	AT	EPT1	01 Dez 1999	99959372.6	26 Sep 2001	E278422	06 Okt 2004	GRT	01 Dez 2019
Ointment Formulation	PAT030724-AU-PCT	AU	PCT1	01 Dez 1999	16569/00	30 Okt 2003	767156	12 Feb 2004	GRT	01 Dez 2019
Ointment Formulation	PAT030724-BE-EPT	BE	EPT1	01 Dez 1999	99959372.6	26 Sep 2001	1135163	06 Okt 2004	GRT	01 Dez 2019
Ointment Formulation	PAT030724-BR-PCT	BR	PCT1	01 Dez 1999	PI9915861.2				TAX	01 Dez 2019
Ointment Formulation	PAT030724-CA-PCT	CA	PCT1	01 Dez 1999	2350884		2350884	03 Jul 2007	GRT	01 Dez 2019
Ointment Formulation	PAT030724-CH-EPT	CH	EPT1	01 Dez 1999	99959372.6	26 Sep 2001	1135163	06 Okt 2004	GRT	01 Dez 2019
Ointment Formulation	PAT030724-CL-NP	CL	NP1	18 Mai 2000	1251/00				FLG	
Ointment Formulation	PAT030724-CN-PCT	CN	PCT1	01 Dez 1999	99814013.9	02 Jan 2002	ZL99814013.9	10 Aug 2005	GRT	01 Dez 2019
Ointment Formulation	PAT030724-CO-NP	CO	NP1	24 Mai 2000	00038226	27 Jun 2002			ABD	
Ointment Formulation	PAT030724-CY-	CY	EPT1	01 Dez 1999	CY04/1101555	26 Sep 2001	1135163	06 Okt 2004	GRT	01 Dez 2019

PATENT

REEL: 033332 FRAME: 0178

Ointment Formulation	PAT030724-MC-EPT	MC	EPT1	01 Dez 1999	99959372.6	26 Sep 2001	1135163	06 Okt 2004	GRT	01 Dez 2019
Ointment Formulation	PAT030724-MX-PCT	MX	PCT1	01 Dez 1999	2001/005514		225756	24 Jan 2005	GRT	01 Dez 2019
Ointment Formulation	PAT030724-MY-NP	MY	NP1	05 Mai 2000	PI20001960		MY-126730-A	31 Okt 2006	GRT	31 Okt 2021
Ointment Formulation	PAT030724-NL-EPT	NL	EPT1	01 Dez 1999	99959372.6	26 Sep 2001	1135163	06 Okt 2004	GRT	01 Dez 2019
Ointment Formulation	PAT030724-NO-PCT	NO	PCT1	01 Dez 1999	20012624				FLG	01 Dez 2019
Ointment Formulation	PAT030724-NZ-PCT	NZ	PCT1	01 Dez 1999	511687	31 Okt 2003	511687	09 Feb 2004	GRT	01 Dez 2019
Ointment Formulation	PAT030724-PE-NP	PE	NP1	29 Mai 2000	5152000-OIN	15 Mrz 2001	3728	20 Okt 2004	GRT	29 Mai 2020
Ointment Formulation	PAT030724-PH-NP	PH	NP1	02 Mai 2000	1-2000-01107	01 Jul 2002	1-2000-01107	26 Mai 2005	GRT	02 Mai 2020
Ointment Formulation	PAT030724-PK-NP	PK	NP1	01 Mai 2000	379/00		139860	24 Dez 2008	GRT	01 Mai 2020
Ointment Formulation	PAT030724-PL-PCT	PL	PCT1	01 Dez 1999	P348750		196628	03 Aug 2007	GRT	01 Dez 2019
Ointment Formulation	PAT030724-PT-EPT	PT	EPT1	01 Dez 1999	99959372.6	26 Sep 2001	1135163	06 Okt 2004	GRT	01 Dez 2019
Ointment Formulation	PAT030724-RO-EPT	RO	EPT1	01 Dez 1999	99959372.6	26 Sep 2001	1135163	06 Okt 2004	GRT	01 Dez 2019
Ointment Formulation	PAT030724-RU-PCT	RU	PCT1	01 Dez 1999	200118049		2234319	17 Feb 2004	GRT	01 Dez 2019
Ointment Formulation	PAT030724-SE-EPT	SE	EPT1	01 Dez 1999	99959372.6	26 Sep 2001	1135163	06 Okt 2004	GRT	01 Dez 2019
Ointment Formulation	PAT030724-SG-PCT	SG	PCT1	01 Dez 1999	200102716-8		80842	30 Jul 2004	GRT	01 Dez 2019
Ointment Formulation	PAT030724-SI-EPT	SI	EPT1	01 Dez 1999	P9930704	26 Sep 2001	1135163	06 Okt 2004	GRT	01 Dez 2019
Ointment Formulation	PAT030724-SK-PCT	SK	PCT1	01 Dez 1999	PV762-2001	06 Nov 2001	285811	26 Jun 2007	GRT	01 Dez 2019
Ointment Formulation	PAT030724-TH-NP	TH	NP1	08 Mai 2000	0001001573	29 Nov 2002			PUB	08 Mai 2020
Ointment Formulation	PAT030724-TR-PCT	TR	PCT1	01 Dez 1999	2001/01547	22 Okt 2001	TR200101547B	21 Nov 2002	GRT	01 Dez 2019
Ointment Formulation	PAT030724-TW-NP	TW	NP1	15 Mai 2000	89109254		1245640	21 Dez 2005	GRT	15 Mai 2020
Ointment Formulation	PAT030724-US-DIV	US	DIV1	31 Mai 2001	09/871367	13 Dez 2001			ADAPT	01 Dez 2019
Ointment Formulation	PAT030724-US-PCT	US	DIV2	03 Nov 2005	11/266639	16 Mrz 2006			PUB	01 Dez 2019

PATENT

REEL: 033332 FRAME: 0180

PROTECTION TYPE	FAMILY NUMBER	CTRY	TYPE	FILING DATE	FILING NUMBER	PUBLICATION	GRANT NUMBER	GRANT DATE	STATUS	EXPIRY
Ointment Formulation	PAT030724-VE-NP	VE	NP1	17 Mai 2000	1065-00	13 Sep 2002			PUB	17 Mai 2020
Ointment Formulation	PAT030724-VN-PCT	VN	PCT1	01 Dez 1999	1-2001-00618	25 Dez 2001	5365	20 Dez 2005	GRT	01 Dez 2019
Ointment Formulation	PAT030724-WO-PCT	WO	PCT1	01 Dez 1999	PCT/EP99/09351	08 Jun 2000			ABD	
Ointment Formulation	PAT030724-ZA-PCT	ZA	PCT1	01 Dez 1999	2001/4529	28 Aug 2002	2001/4529	28 Aug 2002	GRT	01 Dez 2019

Polymorph

PROTECTION TYPE	FAMILY NUMBER	CTRY	TYPE	FILING DATE	FILING NUMBER	PUBLICATION	GRANT NUMBER	GRANT DATE	STATUS	EXPIRY
Polymorph	PAT030055-AR-NP	AR	NP1	26 Jun 1998	P980103094	24 Okt 2001	AR017754B1	15 Jun 2010	GRT	26 Jun 2018
Polymorph	PAT030055-AT-EPT	AT	EPT1	26 Jun 1998	98936392.4	26 Apr 2000	994880	19 Jan 2005	DEPL	26 Jun 2018
Polymorph	PAT030055-AU-PCT	AU	PCT1	26 Jun 1998	85409/98	04 Okt 2001	739211	17 Jan 2002	GRT	26 Jun 2018
Polymorph	PAT030055-BE-EPT	BE	EPT1	26 Jun 1998	98936392.4	26 Apr 2000	994880	19 Jan 2005	GRT	26 Jun 2018
Polymorph	PAT030055-BR-PCT	BR	PCT1	26 Jun 1998	PI98-10956-1	26 Sep 2000		10 Nov 2009	TAX	26 Jun 2018
Polymorph	PAT030055-CA-PCT	CA	PCT1	26 Jun 1998	2290412		2290412	10 Nov 2009	GRT	26 Jun 2018
Polymorph	PAT030055-CH-EPT	CH	EPT1	26 Jun 1998	98936392.4	26 Apr 2000	994880	19 Jan 2005	GRT	26 Jun 2018
Polymorph	PAT030055-CL-NP	CL	NP1	30 Jun 1998	1527-88				FLG	
Polymorph	PAT030055-CN-PCT	CN	PCT1	26 Jun 1998	98806467.7	26 Jul 2000	ZL98806467.7	25 Feb 2004	GRT	26 Jun 2018
Polymorph	PAT030055-CO-DIV	CO	DIV1	09 Jan 2003	98036359 A				FLG	25 Jun 2018
Polymorph	PAT030055-CO-NP	CO	NP1	25 Jun 1998	98036359	24 Jul 2000			PUB	25 Jun 2018
Polymorph	PAT030055-CY-EPT	CY	EPT1	26 Jun 1998	CY05/1100473	26 Apr 2000	1103410	19 Jan 2005	GRT	26 Jun 2018
Polymorph	PAT030055-CZ-PCT	CZ	PCT1	26 Jun 1998	PV1999-4740		297244	31 Aug 2006	GRT	26 Jun 2018
Polymorph	PAT030055-DE-EPT	DE	EPT1	26 Jun 1998	69828692.8	26 Apr 2000	994880	19 Jan 2005	GRT	26 Jun 2018
Polymorph	PAT030055-DK-EPT	DK	EPT1	26 Jun 1998	98936392.4	26 Apr 2000	994880	19 Jan 2005	GRT	26 Jun 2018
Polymorph	PAT030055-EC-NP	EC	NP1	26 Jun 1998	SP-98-2561	12 Apr 1999			PUB	26 Jun 2018
Polymorph	PAT030055-EP-EPT	EP	EPT1	26 Jun 1998	98936392.4	26 Apr 2000	994880	19 Jan 2005	GRT	26 Jun 2018

Polymorph	PAT030055-ES-EPT	ES	EPT1	26 Jun 1998	98936392.4	26 Apr 2000	994880	19 Jan 2005	GRT	26 Jun 2018
Polymorph	PAT030055-FI-EPT	FI	EPT1	26 Jun 1998	98936392.4	26 Apr 2000	994880	19 Jan 2005	GRT	26 Jun 2018
Polymorph	PAT030055-FR-EPT	FR	EPT1	26 Jun 1998	98936392.4	26 Apr 2000	994880	19 Jan 2005	GRT	26 Jun 2018
Polymorph	PAT030055-GB-EPT	GB	EPT1	26 Jun 1998	98936392.4	26 Apr 2000	994880	19 Jan 2005	GRT	26 Jun 2018
Polymorph	PAT030055-GB-NP	GB	NP1	30 Jun 1997	9713730.1				ABD	30 Jun 2017
Polymorph	PAT030055-GR-EPT	GR	EPT1	26 Jun 1998	98936392.4	26 Apr 2000	994880	19 Jan 2005	GRT	26 Jun 2018
Polymorph	PAT030055-HK-FPR	HK	FPR1	25 Okt 2000	00106806.1		HK1028587	19 Aug 2005	GRT	26 Jun 2018
Polymorph	PAT030055-HU-PCT	HU	PCT1	26 Jun 1998	P0003053	28 Feb 2001			PUB	26 Jun 2018
Polymorph	PAT030055-ID-PCT	ID	PCT1	26 Jun 1998	W-991692	31 Aug 2000	ID0015843	20 Mai 2005	GRT	26 Jun 2018
Polymorph	PAT030055-IE-EPT	IE	EPT1	26 Jun 1998	98936392.4	26 Apr 2000	994880	19 Jan 2005	GRT	26 Jun 2018
Polymorph	PAT030055-IL-PCT	IL	PCT1	26 Jun 1998	132761	12 Mrz 2006	132761	13 Jun 2006	GRT	26 Jun 2018
Polymorph	PAT030055-IN-DIV	IN	DIV1	30 Nov 2006	2222ICHE/2006				FLG	29 Jun 2018
Polymorph	PAT030055-IN-DIV02	IN	DIV2	16 Apr 2010	1077ICHE/2010				FLG	29 Jun 2018
Polymorph	PAT030055-IN-NP	IN	NP1	29 Jun 1998	1440IMAS/98				FLG	29 Jun 2018
Polymorph	PAT030055-IT-EPT	IT	EPT1	26 Jun 1998	98936392.4	26 Apr 2000	994880	19 Jan 2005	GRT	26 Jun 2018
Polymorph	PAT030055-JP-PCT	JP	PCT1	26 Jun 1998	5062871999				PUBG	26 Jun 2018
Polymorph	PAT030055-JP-PCTD	JP	PCTD1	01 Mrz 2006	2006-055107	15 Jun 2006	4504923	30 Apr 2010	PUBG	26 Jun 2018
Polymorph	PAT030055-KR-PCT	KR	PCT1	26 Jun 1998	10-1999-7010048				GRT	26 Jun 2018
Polymorph	PAT030055-LU-EPT	LU	EPT1	26 Jun 1998	98936392.4	26 Apr 2000	994880	19 Jan 2005	GRT	26 Jun 2018
Polymorph	PAT030055-MC-EPT	MC	EPT1	26 Jun 1998	98936392.4	26 Apr 2000	994880	19 Jan 2005	GRT	26 Jun 2018
Polymorph	PAT030055-MX-PCT	MX	PCT1	26 Jun 1998	1999/011294		215873	15 Aug 2003	GRT	26 Jun 2018
Polymorph	PAT030055-MY-NP	MY	NP1	29 Jun 1998	P198002955		MY-118718-A	31 Jan 2005	GRT	31 Jan 2020
Polymorph	PAT030055-NL-EPT	NL	EPT1	26 Jun 1998	98936392.4	26 Apr 2000	994880	19 Jan 2005	GRT	26 Jun 2018
Polymorph	PAT030055-NO-PCT	NO	PCT1	26 Jun 1998	19995908	02 Dez 1999	312765	01 Jul 2002	GRT	26 Jun 2018
Polymorph	PAT030055-NZ-PCT	NZ	PCT1	26 Jun 1998	500994		500994	17 Dez 2001	GRT	26 Jun 2018
Polymorph	PAT030055-PE-NP	PE	NP1	26 Jun 1998	568/1998-OIN	29 Okt 1999	3335	22 Jan 2004	GRT	26 Jun 2018
Polymorph	PAT030055-PH-NP	PH	NP1	29 Jun 1998	1-1998-01665	26 Mrz 2001	1-1998-01665	26 Mai 2003	GRT	29 Jun 2018
Polymorph	PAT030055-PK-DIV	PK	DIV1	07 Okt 2006	1173/2008		140364	08 Dez 2009	GRT	30 Jun 2018
Polymorph	PAT030055-PK-NP	PK	NP1	29 Jun 1998	666/98		140339	13 Jan 2010	GRT	30 Jun 2017

Polymorph	PAT030055-PL-PCT	PL	PCT1	26 Jun 1998	P336719			192761	23 Jun 2006	GRT	26 Jun 2018
Polymorph	PAT030055-PT-EPT	PT	EPT1	26 Jun 1998	98936392.4	26 Apr 2000		994880	19 Jan 2005	GRT	26 Jun 2018
Polymorph	PAT030055-RO-EPT	RO	EPT1	26 Jun 1998	98936392.4	26 Apr 2000		994880	19 Jan 2005	GRT	26 Jun 2018
Polymorph	PAT030055-RU-PCT	RU	PCT1	26 Jun 1998	2000101826			2219181	26 Jun 2003	GRT	26 Jun 2018
Polymorph	PAT030055-SA-NP	SA	NP1	01 Mrz 2004	04250016					FLG	01 Mrz 2024
Polymorph	PAT030055-SE-EPT	SE	EPT1	26 Jun 1998	98936392.4	26 Apr 2000		994880	19 Jan 2005	GRT	26 Jun 2018
Polymorph	PAT030055-SG-PCT	SG	PCT1	26 Jun 1998	9905221-9			68525	29 Jan 2002	GRT	26 Jun 2018
Polymorph	PAT030055-SI-EPT	SI	EPT1	26 Jun 1998	P9830759	26 Apr 2000		994880	19 Jan 2005	GRT	26 Jun 2018
Polymorph	PAT030055-SK-PCT	SK	PCT1	26 Jun 1998	PP1866-89	16 Mai 2000		285665	26 Mrz 2007	PUBG	26 Jun 2018
Polymorph	PAT030055-TH-NP	TH	NP1	17 Jun 1998	44471	11 Okt 2000				PUB	17 Jun 2018
Polymorph	PAT030055-TR-PCT	TR	PCT1	26 Jun 1998	1999/03189	21 Jun 2000		TR199903189	21 Jul 2009	GRT	26 Jun 2018
Polymorph	PAT030055-TW-NP	TW	NP1	21 Jul 1998	87111867	11 Sep 2003		NI-186245	29 Jan 2004	GRT	21 Jul 2018
Polymorph	PAT030055-US-CNT	US	CNT1	17 Okt 2000	09/690404			6423722	23 Jul 2002	GRT	26 Jun 2018
Polymorph	PAT030055-US-PCT	US	PCT1	26 Jun 1998						ABD	26 Jun 2018
Polymorph	PAT030055-VE-NP	VE	NP1	25 Jun 1998	1385-98	22 Nov 2000				PUB	25 Jun 2018
Polymorph	PAT030055-VN-PCT	VN	PCT1	26 Jun 1998	S19990902	25 Sep 2000		3823	29 Sep 2003	GRT	26 Jun 2018
Polymorph	PAT030055-WO-PCT	WO	PCT1	26 Jun 1998	PCTEP98/03929	14 Jan 1999				ABD	
Polymorph	PAT030055-ZA-NP	ZA	NP1	29 Jun 1998	98/5655	24 Feb 1999		98/5655	24 Feb 1999	GRT	29 Jun 2018

Process

PROTECTION TYPE	FAMILY NUMBER	CTRY	TYPE	FILING DATE	FILING NUMBER	PUBLICATION	GRANT NUMBER	GRANT DATE	STATUS	EXPIRY
Process	PAT039977-AE-PCT	AE	PCT1	10 Okt 2005	P308/07				DEPL	10 Okt 2025
Process	PAT039977-AR-NP	AR	NP1	11 Okt 2005	P050104257	10 Jan 2007			PUB	11 Okt 2025
Process	PAT039977-AU-PCT	AU	PCT1	10 Okt 2005	2005293799	26 Feb 2009	2005293799	11 Jun 2009	GRT	10 Okt 2025
Process	PAT039977-BR-PCT	BR	PCT1	10 Okt 2005	P10516873.2	23 Sep 2008			TAX	10 Okt 2025
Process	PAT039977-CA-PCT	CA	PCT1	10 Okt 2005	2581046				DEPL	10 Okt 2025
Process	PAT039977-CL-NP	CL	NP1	11 Okt 2005	2667/05	09 Jun 2006			PUB	
Process	PAT039977-CN-PCT	CN	PCT1	10 Okt 2005	200580033307.0	05 Sep 2007	200580033307.0	09 Jun 2010	GRT	10 Okt 2025
Process	PAT039977-CO-PCT	CO	PCT1	10 Okt 2005	07035148	31 Mrz 2008			PUB	10 Okt 2025
Process	PAT039977-DZ-PCT	DZ	PCT1	10 Okt 2005	070280				DEPL	10 Okt 2025

Process	PAT033977-EC-PCT	EC	PCT1	10 Okt 2005	07-7384PCT	30 Mai 2007				PUB	10 Okt 2025
Process	PAT033977-EG-PCT	EG	PCT1	10 Okt 2005	366/2007					DEPL	10 Okt 2025
Process	PAT033977-EP-EPT	EP	EPT1	10 Okt 2005	05793907.6	04 Jul 2007				PUB	10 Okt 2025
Process	PAT033977-GB-NP	GB	NP1	12 Okt 2004	0422643.7					ABD	12 Okt 2024
Process	PAT033977-GB-NP02	GB	NP2	16 Dez 2004	0427599.6					ABD	16 Dez 2024
Process	PAT033977-GC-NP	GC	NP1	12 Okt 2005	GCC/P/2005/5257					ABD	
Process	PAT033977-GC-NP02	GC	NP2	31 Jan 2006	GCC/P/2006/5743					FLG	31 Jan 2026
Process	PAT033977-GT-NP	GT	NP1	07 Okt 2005	PI20050282			5290	01 Jun 2009	GRT	07 Okt 2025
Process	PAT033977-HK-FPR	HK	FPR1	05 Okt 2007	07110850.1	22 Feb 2008				PUB	10 Okt 2025
Process	PAT033977-ID-PCT	ID	PCT1	10 Okt 2005	W00200701131	06 Sep 2007				PUB	10 Okt 2025
Process	PAT033977-IL-PCT	IL	PCT1	10 Okt 2005	182307					DEPL	10 Okt 2025
Process	PAT033977-IN-PCT	IN	PCT1	10 Okt 2005	2363/CHENP/07					DEPL	10 Okt 2025
Process	PAT033977-IQ-NP	IQ	NP1	26 Sep 2005	145/2005					FLG	26 Sep 2025
Process	PAT033977-JO-NP	JO	NP1	09 Okt 2005	138/2005					FLG	12 Okt 2024
Process	PAT033977-JP-PCT	JP	PCT1	10 Okt 2005	2007-536064	15 Mai 2008				PUB	10 Okt 2025
Process	PAT033977-KR-PCT	KR	PCT1	10 Okt 2005	2007-7008216					DEPL	10 Okt 2025
Process	PAT033977-LB-NP	LB	NP1	05 Okt 2005	7309			7309	28 Nov 2005	GRT	05 Okt 2025
Process	PAT033977-MA-PCT	MA	PCT1	10 Okt 2005	PV29826			28932	01 Okt 2007	GRT	10 Okt 2025
Process	PAT033977-MT-NP	MT	NP1	11 Okt 2005	3036			3036	19 Apr 2006	GRT	11 Okt 2025
Process	PAT033977-MX-PCT	MX	PCT1	10 Okt 2005	MX/07/004258	22 Jan 2008				GRT	10 Okt 2025
Process	PAT033977-MY-NP	MY	NP1	11 Okt 2005	PI20054764			MY-140880-A	29 Jan 2010	GRT	11 Okt 2025
Process	PAT033977-NO-PCT	NO	PCT1	10 Okt 2005	20072127					DEPL	10 Okt 2025
Process	PAT033977-NZ-PCT	NZ	PCT1	10 Okt 2005	554010	30 Okt 2009		554010	11 Feb 2010	GRT	10 Okt 2025
Process	PAT033977-PE-NP	PE	NP1	11 Okt 2005	001202/2005-OIN	17 Aug 2006		005396	19 Aug 2009	GRT	11 Okt 2025
Process	PAT033977-PH-PCT	PH	PCT1	10 Okt 2005	1-2007-500690	20 Apr 2006				DEPL	10 Okt 2025
Process	PAT033977-PK-NP	PK	NP1	11 Okt 2005	959/2005			140162	08 Mrz 2010	GRT	12 Okt 2024
Process	PAT033977-RU-PCT	RU	PCT1	10 Okt 2005	2007117497			2394037	10 Jul 2010	GRT	10 Okt 2025
Process	PAT033977-SG-PCT	SG	PCT1	10 Okt 2005	200702285.8			131280	30 Okt 2009	GRT	10 Okt 2025
Process	PAT033977-TH-NP	TH	NP1	28 Sep 2005	0501004552	28 Sep 2006				PUB	28 Sep 2025
Process	PAT033977-TN-PCT	TN	PCT1	10 Okt 2005	SN07133					DEPL	10 Okt 2025
Process	PAT033977-TW-NP	TW	NP1	11 Okt 2005	94135403	01 Aug 2006				PUB	11 Okt 2025
Process	PAT033977-US-PCT	US	PCT1	10 Okt 2005	11/575757	20 Mrz 2008		7514554	07 Apr 2009	GRT	10 Okt 2025

Process	PAT033977-VE-NP	VE	NP1	11 Okt 2005	2086-05				FLG	11 Okt 2025
Process	PAT033977-WO-PCT	WO	PCT1	10 Okt 2005	PCT/EP2005/010889	20 Apr 2006			PUB	
Process	PAT033977-ZA-PCT	ZA	PCT1	10 Okt 2005	2007/02419		2007/02419	27 Aug 2008	GRT	10 Okt 2025

Process II

PROTECTION TYPE	FAMILY NUMBER	CTRY	TYPE	FILING DATE	FILING NUMBER	PUBLICATION	GRANT NUMBER	GRANT DATE	STATUS	EXPIRY
Process	PAT100-8345-GB-NP	GB	NP1	11 Sep 1996	9618952.7				ABD	
Process	PAT100-8345-US-CNT	US	CNT1	18 Mrz 1999	09/271672				ABD	10 Sep 2017
Process	PAT100-8345-US-CNT02	US	CNT2	03 Nov 2006	11/592852	05 Apr 2007			ABD	
Process	PAT100-8345-US-CNT04	US	CNT4	31 Aug 2000	08/652295				ABD	10 Sep 2017
Process	PAT100-8345-US-DIV	US	DIV1	23 Jul 2003	10/624997	18 Mrz 2004			ADAPT	
Process	PAT100-8345-US-DIV02	US	DIV2	23 Jul 2003	10/625142		7148346	12 Dez 2006	GRT	31 Dez 2017
Process	PAT100-8345-US-NP	US	NP1	10 Sep 1997	08/926722				ABD	10 Sep 2017